No connection

Search Results

NVCR vs WVE

NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%
WVE
Wave Life Sciences Ltd.
BEARISH
Price
$7.31
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
NVCR
--
WVE
--
Forward P/E
NVCR
-10.44
WVE
-5.46
P/B Ratio
NVCR
4.02
WVE
2.65
P/S Ratio
NVCR
2.11
WVE
32.21
EV/EBITDA
NVCR
-8.77
WVE
-3.77

Profitability

Gross Margin
NVCR
74.8%
WVE
0.0%
Operating Margin
NVCR
-21.33%
WVE
-327.44%
Profit Margin
NVCR
-20.79%
WVE
0.0%
ROE
NVCR
-38.89%
WVE
-54.97%
ROA
NVCR
-9.06%
WVE
-27.18%

Growth

Revenue Growth
NVCR
8.1%
WVE
-79.4%
Earnings Growth
NVCR
--
WVE
--

Financial Health

Debt/Equity
NVCR
0.73
WVE
0.03
Current Ratio
NVCR
2.9
WVE
6.47
Quick Ratio
NVCR
2.51
WVE
6.35

Dividends

Dividend Yield
NVCR
--
WVE
--
Payout Ratio
NVCR
0.0%
WVE
0.0%

AI Verdict

NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)
WVE BEARISH

WVE exhibits severe financial distress from a deterministic standpoint, highlighted by a critical Piotroski F-Score of 1/9. While the company maintains a strong liquidity position with a current ratio of 6.47 and negligible debt, these are offset by a catastrophic 79.4% decline in year-over-year revenue and an operating margin of -327.44%. There is a stark divergence between the 'Strong Buy' analyst consensus and the bearish reality of insider selling by the CEO and CFO, alongside a recent 37% price collapse. The valuation is purely speculative, as evidenced by a Price/Sales ratio of 32.21 in the face of shrinking revenues.

Strengths
Very low Debt/Equity ratio (0.03)
Strong short-term liquidity (Current Ratio 6.47)
High analyst target price ($24.93) suggesting potential clinical catalysts
Risks
Severe revenue contraction (-79.4% YoY)
Extreme operational inefficiency (Operating Margin -327.44%)
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)

Compare Another Pair

NVCR vs WVE: Head-to-Head Comparison

This page compares NovoCure Limited (NVCR) and Wave Life Sciences Ltd. (WVE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile